Kevin Strange, Ph.D. (left) and Voot P. Yin, Ph.D. (IMAGE)

MDI Biological Laboratory

Kevin Strange, Ph.D. (left) and Voot P. Yin, Ph.D.

Caption

Kevin Strange, Ph.D. (left), is chief executive officer of Novo Biosciences, a co-inventor of MSI-1436 and president of the MDI Biological Laboratory in Bar Harbor, Maine; Voot P. Yin, Ph.D., is chief scientific officer of Novo Biosciences, a co-inventor of MSI-1436, principal investigator for the Small Business Innovation Research (SBIR) grant from the National Institutes of Health and a scientist at the MDI Biological Laboratory. Novo Biosciences, which is a spinoff of the MDI Biological Laboratory, received the two-year, $1.5 million SBIR grant for the development of MSI-1436 as a potential regenerative medicine therapy for the treatment of patients who have suffered an acute heart attack. The grant will allow the company to move ahead with studies of the effectiveness of MSI-1436 in pigs, the critical next step in moving the drug candidate into clinical trials. MSI-1436 has already been demonstrated to regenerate damaged heart muscle and improve heart function in adult zebrafish and mice.

Credit

MDI Biological Laboratory

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.